Selected research
Industry Research
AI Oncology/Cancer Early Screening Industry Research Report 2026
Market perspective
The global AI Oncology/Cancer Early Screening market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the AI Oncology/Cancer Early Screening market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the AI Oncology/Cancer Early Screening market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the AI Oncology/Cancer Early Screening market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of AI Oncology/Cancer Early Screening include Tempus AI, Grail, Guardant Health, PathAI, Google(DeepMind), Philips Healthcare, IBM, Azra AI and Siemens Healthineers, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global AI Oncology/Cancer Early Screening market in terms of revenue (US$ million) and, where applicable, service volume (Unit), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Unit) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to AI Oncology/Cancer Early Screening.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
AI Oncology/Cancer Early Screening Market by Company
Tempus AI
Grail
Guardant Health
PathAI
Google(DeepMind)
Philips Healthcare
IBM
Azra AI
Siemens Healthineers
GE Healthcare
Intel
ConcertAI
NVIDIA Developer
Digital Diagnostics
Median Technologies
Alibaba Group
ByteDance
BGI Genomics
Guangzhou Kingmed Diagnostics Group Co., Ltd.
Amoy Diagnostics Co.,Ltd.
Tencent Miying
AI Oncology/Cancer Early Screening Segment by Type
Based on Medical Imaging
Based on Multi-omics Data
AI Oncology/Cancer Early Screening Segment by Application
Lung Cancer
Digestive System Tumors (Colorectal Cancer/Pancreatic Cancer/Liver Cancer/Gastric Cancer)
Breast Cancer and Gynecological Tumors (Ovarian Cancer/Cervical Cancer)
Urinary System Tumors (Bladder Cancer)
Central Nervous System Tumors
Soft Tissue and Bone Tumors
Thyroid Cancer and Melanoma
AI Oncology/Cancer Early Screening Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Oncology/Cancer Early Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of AI Oncology/Cancer Early Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Oncology/Cancer Early Screening.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of AI Oncology/Cancer Early Screening companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Based on Medical Imaging
- Based on Multi-omics Data
Applications
- Lung Cancer
- Digestive System Tumors (Colorectal Cancer/Pancreatic Cancer/Liver Cancer/Gastric Cancer)
- Breast Cancer and Gynecological Tumors (Ovarian Cancer/Cervical Cancer)
- Urinary System Tumors (Bladder Cancer)
- Central Nervous System Tumors
- Soft Tissue and Bone Tumors
- Thyroid Cancer and Melanoma
Companies covered
- Tempus AI
- Grail
- Guardant Health
- PathAI
- Google(DeepMind)
- Philips Healthcare
- IBM
- Azra AI
- Siemens Healthineers
- GE Healthcare
- Intel
- ConcertAI
- NVIDIA Developer
- Digital Diagnostics
- Median Technologies
- Alibaba Group
- ByteDance
- BGI Genomics
- Guangzhou Kingmed Diagnostics Group Co., Ltd.
- Amoy Diagnostics Co.,Ltd.
- Tencent Miying
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 AI Oncology/Cancer Early Screening by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Based on Medical Imaging
- 2.2.3 Based on Multi-omics Data
- 2.3 AI Oncology/Cancer Early Screening by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Lung Cancer
- 2.3.3 Digestive System Tumors (Colorectal Cancer/Pancreatic Cancer/Liver Cancer/Gastric Cancer)
- 2.3.4 Breast Cancer and Gynecological Tumors (Ovarian Cancer/Cervical Cancer)
- 2.3.5 Urinary System Tumors (Bladder Cancer)
- 2.3.6 Central Nervous System Tumors
- 2.3.7 Soft Tissue and Bone Tumors
- 2.3.8 Thyroid Cancer and Melanoma
- 2.4 Assumptions and Limitations
3 AI Oncology/Cancer Early Screening Breakdown Data by Type
- 3.1 Global AI Oncology/Cancer Early Screening Historic Market Size by Type (2021-2026)
- 3.2 Global AI Oncology/Cancer Early Screening Forecasted Market Size by Type (2027-2032)
4 AI Oncology/Cancer Early Screening Breakdown Data by Application
- 4.1 Global AI Oncology/Cancer Early Screening Historic Market Size by Application (2021-2026)
- 4.2 Global AI Oncology/Cancer Early Screening Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global AI Oncology/Cancer Early Screening Market Perspective (2021-2032)
- 5.2 Global AI Oncology/Cancer Early Screening Growth Trends by Region
- 5.2.1 Global AI Oncology/Cancer Early Screening Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 AI Oncology/Cancer Early Screening Historic Market Size by Region (2021-2026)
- 5.2.3 AI Oncology/Cancer Early Screening Forecasted Market Size by Region (2027-2032)
- 5.3 AI Oncology/Cancer Early Screening Market Dynamics
- 5.3.1 AI Oncology/Cancer Early Screening Industry Trends
- 5.3.2 AI Oncology/Cancer Early Screening Market Drivers
- 5.3.3 AI Oncology/Cancer Early Screening Market Challenges
- 5.3.4 AI Oncology/Cancer Early Screening Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top AI Oncology/Cancer Early Screening Players by Revenue
- 6.1.1 Global Top AI Oncology/Cancer Early Screening Players by Revenue (2021-2026)
- 6.1.2 Global AI Oncology/Cancer Early Screening Revenue Market Share by Players (2021-2026)
- 6.2 Global AI Oncology/Cancer Early Screening Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of AI Oncology/Cancer Early Screening Head Office and Area Served
- 6.4 Global AI Oncology/Cancer Early Screening Players, Product Type & Application
- 6.5 Global AI Oncology/Cancer Early Screening Manufacturers Established Date
- 6.6 Global AI Oncology/Cancer Early Screening Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America AI Oncology/Cancer Early Screening Market Size (2021-2032)
- 7.2 North America AI Oncology/Cancer Early Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America AI Oncology/Cancer Early Screening Market Size by Country (2021-2026)
- 7.4 North America AI Oncology/Cancer Early Screening Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe AI Oncology/Cancer Early Screening Market Size (2021-2032)
- 8.2 Europe AI Oncology/Cancer Early Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe AI Oncology/Cancer Early Screening Market Size by Country (2021-2026)
- 8.4 Europe AI Oncology/Cancer Early Screening Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific AI Oncology/Cancer Early Screening Market Size (2021-2032)
- 9.2 Asia-Pacific AI Oncology/Cancer Early Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific AI Oncology/Cancer Early Screening Market Size by Country (2021-2026)
- 9.4 Asia-Pacific AI Oncology/Cancer Early Screening Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America AI Oncology/Cancer Early Screening Market Size (2021-2032)
- 10.2 South America AI Oncology/Cancer Early Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America AI Oncology/Cancer Early Screening Market Size by Country (2021-2026)
- 10.4 South America AI Oncology/Cancer Early Screening Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa AI Oncology/Cancer Early Screening Market Size (2021-2032)
- 11.2 Middle East & Africa AI Oncology/Cancer Early Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa AI Oncology/Cancer Early Screening Market Size by Country (2021-2026)
- 11.4 Middle East & Africa AI Oncology/Cancer Early Screening Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Tempus AI
- 12.1.1 Tempus AI Company Information
- 12.1.2 Tempus AI Business Overview
- 12.1.3 Tempus AI Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.1.4 Tempus AI AI Oncology/Cancer Early Screening Product Portfolio
- 12.1.5 Tempus AI Recent Developments
- 12.2 Grail
- 12.2.1 Grail Company Information
- 12.2.2 Grail Business Overview
- 12.2.3 Grail Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.2.4 Grail AI Oncology/Cancer Early Screening Product Portfolio
- 12.2.5 Grail Recent Developments
- 12.3 Guardant Health
- 12.3.1 Guardant Health Company Information
- 12.3.2 Guardant Health Business Overview
- 12.3.3 Guardant Health Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.3.4 Guardant Health AI Oncology/Cancer Early Screening Product Portfolio
- 12.3.5 Guardant Health Recent Developments
- 12.4 PathAI
- 12.4.1 PathAI Company Information
- 12.4.2 PathAI Business Overview
- 12.4.3 PathAI Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.4.4 PathAI AI Oncology/Cancer Early Screening Product Portfolio
- 12.4.5 PathAI Recent Developments
- 12.5 Google(DeepMind)
- 12.5.1 Google(DeepMind) Company Information
- 12.5.2 Google(DeepMind) Business Overview
- 12.5.3 Google(DeepMind) Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.5.4 Google(DeepMind) AI Oncology/Cancer Early Screening Product Portfolio
- 12.5.5 Google(DeepMind) Recent Developments
- 12.6 Philips Healthcare
- 12.6.1 Philips Healthcare Company Information
- 12.6.2 Philips Healthcare Business Overview
- 12.6.3 Philips Healthcare Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.6.4 Philips Healthcare AI Oncology/Cancer Early Screening Product Portfolio
- 12.6.5 Philips Healthcare Recent Developments
- 12.7 IBM
- 12.7.1 IBM Company Information
- 12.7.2 IBM Business Overview
- 12.7.3 IBM Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.7.4 IBM AI Oncology/Cancer Early Screening Product Portfolio
- 12.7.5 IBM Recent Developments
- 12.8 Azra AI
- 12.8.1 Azra AI Company Information
- 12.8.2 Azra AI Business Overview
- 12.8.3 Azra AI Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.8.4 Azra AI AI Oncology/Cancer Early Screening Product Portfolio
- 12.8.5 Azra AI Recent Developments
- 12.9 Siemens Healthineers
- 12.9.1 Siemens Healthineers Company Information
- 12.9.2 Siemens Healthineers Business Overview
- 12.9.3 Siemens Healthineers Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.9.4 Siemens Healthineers AI Oncology/Cancer Early Screening Product Portfolio
- 12.9.5 Siemens Healthineers Recent Developments
- 12.10 GE Healthcare
- 12.10.1 GE Healthcare Company Information
- 12.10.2 GE Healthcare Business Overview
- 12.10.3 GE Healthcare Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.10.4 GE Healthcare AI Oncology/Cancer Early Screening Product Portfolio
- 12.10.5 GE Healthcare Recent Developments
- 12.11 Intel
- 12.11.1 Intel Company Information
- 12.11.2 Intel Business Overview
- 12.11.3 Intel Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.11.4 Intel AI Oncology/Cancer Early Screening Product Portfolio
- 12.11.5 Intel Recent Developments
- 12.12 ConcertAI
- 12.12.1 ConcertAI Company Information
- 12.12.2 ConcertAI Business Overview
- 12.12.3 ConcertAI Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.12.4 ConcertAI AI Oncology/Cancer Early Screening Product Portfolio
- 12.12.5 ConcertAI Recent Developments
- 12.13 NVIDIA Developer
- 12.13.1 NVIDIA Developer Company Information
- 12.13.2 NVIDIA Developer Business Overview
- 12.13.3 NVIDIA Developer Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.13.4 NVIDIA Developer AI Oncology/Cancer Early Screening Product Portfolio
- 12.13.5 NVIDIA Developer Recent Developments
- 12.14 Digital Diagnostics
- 12.14.1 Digital Diagnostics Company Information
- 12.14.2 Digital Diagnostics Business Overview
- 12.14.3 Digital Diagnostics Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.14.4 Digital Diagnostics AI Oncology/Cancer Early Screening Product Portfolio
- 12.14.5 Digital Diagnostics Recent Developments
- 12.15 Median Technologies
- 12.15.1 Median Technologies Company Information
- 12.15.2 Median Technologies Business Overview
- 12.15.3 Median Technologies Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.15.4 Median Technologies AI Oncology/Cancer Early Screening Product Portfolio
- 12.15.5 Median Technologies Recent Developments
- 12.16 Alibaba Group
- 12.16.1 Alibaba Group Company Information
- 12.16.2 Alibaba Group Business Overview
- 12.16.3 Alibaba Group Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.16.4 Alibaba Group AI Oncology/Cancer Early Screening Product Portfolio
- 12.16.5 Alibaba Group Recent Developments
- 12.17 ByteDance
- 12.17.1 ByteDance Company Information
- 12.17.2 ByteDance Business Overview
- 12.17.3 ByteDance Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.17.4 ByteDance AI Oncology/Cancer Early Screening Product Portfolio
- 12.17.5 ByteDance Recent Developments
- 12.18 BGI Genomics
- 12.18.1 BGI Genomics Company Information
- 12.18.2 BGI Genomics Business Overview
- 12.18.3 BGI Genomics Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.18.4 BGI Genomics AI Oncology/Cancer Early Screening Product Portfolio
- 12.18.5 BGI Genomics Recent Developments
- 12.19 Guangzhou Kingmed Diagnostics Group Co., Ltd.
- 12.19.1 Guangzhou Kingmed Diagnostics Group Co., Ltd. Company Information
- 12.19.2 Guangzhou Kingmed Diagnostics Group Co., Ltd. Business Overview
- 12.19.3 Guangzhou Kingmed Diagnostics Group Co., Ltd. Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.19.4 Guangzhou Kingmed Diagnostics Group Co., Ltd. AI Oncology/Cancer Early Screening Product Portfolio
- 12.19.5 Guangzhou Kingmed Diagnostics Group Co., Ltd. Recent Developments
- 12.20 Amoy Diagnostics Co.,Ltd.
- 12.20.1 Amoy Diagnostics Co.,Ltd. Company Information
- 12.20.2 Amoy Diagnostics Co.,Ltd. Business Overview
- 12.20.3 Amoy Diagnostics Co.,Ltd. Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.20.4 Amoy Diagnostics Co.,Ltd. AI Oncology/Cancer Early Screening Product Portfolio
- 12.20.5 Amoy Diagnostics Co.,Ltd. Recent Developments
- 12.21 Tencent Miying
- 12.21.1 Tencent Miying Company Information
- 12.21.2 Tencent Miying Business Overview
- 12.21.3 Tencent Miying Revenue in AI Oncology/Cancer Early Screening Business (2021-2026)
- 12.21.4 Tencent Miying AI Oncology/Cancer Early Screening Product Portfolio
- 12.21.5 Tencent Miying Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst